Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin autofluorescence promises noninvasive risk assessment for CHD

This article was originally published in Clinica

Executive Summary

A table-top optical tissue monitor for measuring fluorescence patterns in the skin in a noninvasive fashion could provide doctors with a rapid new method of assessing high-risk heart disease (CHD) patients, a study has shown. The device, which was developed by Dutch firm DiagnOptics and was recently CE-marked for sale in Europe, assesses the accumulation in skin cells of a class of compounds known as advanced glycation end products (AGEs). AGEs, which result from glycation and oxidation of proteins, lipids or nucleic acids, are considered to play a pivotal role in the development of chronic complications of conditions such as diabetes, renal failure and atherosclerosis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT056973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel